Publications discussed by Dr Pegram

Citron ML et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21(8):1431-9. Abstract

Hurley J et al. Neoadjuvant herceptin/taxotere/cisplatin in the treatment of locally advanced and inflammatory breast cancer. Proc Am Soc Clin Oncol 2002:Abstract 196.

Konecny G et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 2003;95(2):142-53. Abstract

Miller KD et al. Phase III trial of capecitabine (Xeloda®) plus bevacizumab (Avastin™) versus capecitabine alone in women with metastatic breast cancer (MBC) previously treated with an anthracycline and a taxane. Breast Cancer Res Treat 2002;76 (Suppl 1); Abstract 36.

Pegram MD et al. Trastuzumab and chemotherapeutics: Drug interactions and synergies. Semin Oncol 2000;27(6 Suppl 11):21-5; discussion 92-100. Abstract

Pegram MD et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neuoverexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998;16(8):2659-71. Abstract

Pegram MD and Slamon DJ. Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: Evidence for receptor-enhanced chemosensitivity. Semin Oncol 1999;26(4 Suppl 12):89-95. Abstract

Robert N et al. Phase III comparative study of trastuzumab and paclitaxel with and without carboplatin in patients with HER-2/neu positive advanced breast cancer. Breast Cancer Res Treat 2002; 76 (Suppl 1); Abstract 35.

Slamon DJ et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New England Journal of Medicine 2001; 344:783-92. Abstract

Platinum compounds in breast cancer

Ligibel JA and Winer EP. Trastuzumab/chemotherapy combinations in metastatic breast cancer. Semin Oncol 2002;29(3 Suppl 11):38-43. Abstract

Martin M. Platinum compounds in the treatment of advanced breast cancer. Clin Breast Cancer 2001;2(3):190-208; discussion 209. Abstract

Nabholtz JM et al. HER2-positive breast cancer: Update on Breast Cancer International Research Group trials. Clin Breast Cancer 2002;3 (Suppl 2):75-9. Abstract

Nabholtz JM et al. Docetaxel in the treatment of breast cancer: An update on recent studies. Semin Oncol 2002;29(3 Suppl 12):28-34. Abstract

Spigel DR and Burstein HJ. HER2 overexpressing metastatic breast cancer. Curr Treat Options Onco. 2002;3(2):163-74. Abstract

Bevacizumab

Biganzoli L et al. Moving forward with capecitabine: A glimpse of the future. Oncologist 2002,7(Suppl 6):29-35. Abstract

Burstein HJ et al. Phase II trial of the anti-VEGF antibody bevacizumab in combination with vinorelbine for refractory advanced breast cancer. Breast Cancer Res Treat 2002;Abstract 446.

Gray R et al. The safety of adding angiogenesis inhibition into treatment for colorectal, breast, and lung cancer: The Eastern Cooperative Oncology Group's (ECOG) experience with bevacizumab (anti-VEGF). Proc ASCO 2003;Abstract 825.

Hillan KJ et al. The role of VEGF expression in response to bevacizumab plus capecitabine in metastatic breast cancer (MBC). Proc ASCO 2003;Abstract 766.

Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: Therapeutic implications. Semin Oncol 2002;29(6 Suppl 16):10-4. Abstract

Jain RK. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Semin Oncol 2002;29(6 Suppl 16):3-9. Abstract

Miller KD et al. Phase III trial of capecitabine (Xeloda®) plus bevacizumab (Avastin™) versus capecitabine alone in women with metastatic breast cancer (MBC) previously treated with an anthracycline and a taxane. Breast Cancer Res Treat 2002;Abstract 36.

Rosen LS. Clinical experience with angiogenesis signaling inhibitors: Focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control 2002;9(2 Suppl):36-44. Abstract

Home · Search